advise	The findings suggest that the dosage of <e10> S-ketamine </e10> should be reduced in patients receiving <e20> ticlopidine </e20> .
advise	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with <e10> tamoxifen </e10> for breast cancer, especially <e22> SSRI_antidepressants </e22> such as paroxetine and fluoxetine .
advise	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with <e10> tamoxifen </e10> for breast cancer, especially SSRI_antidepressants such as <e20> paroxetine </e20> and fluoxetine .
advise	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with <e10> tamoxifen </e10> for breast cancer, especially SSRI_antidepressants such as paroxetine and <e20> fluoxetine </e20> .
advise	If in certain cases, an <e12> antidepressant </e12> is considered necessary, it may be advisable to replace <e20> tamoxifen </e20> with anastrozole .
advise	Regulatory agencies state that the combination of <e10> clopidogrel </e10> and the CYP2C19 inhibitors <e20> omeprazole </e20> and esomeprazole should be avoided.
advise	Regulatory agencies state that the combination of <e10> clopidogrel </e10> and the CYP2C19 inhibitors omeprazole and <e20> esomeprazole </e20> should be avoided.
advise	Co-administration of <e11> ZETIA </e11> with <e22> fibrates </e22> is not recommended until use in patients is studied.
advise	Patients who take both <e10> ezetimibe </e10> and <e20> cyclosporine </e20> should be carefully monitored.
advise	When <e11> DIFLUCAN </e11> is used concomitantly with these or other <e22> sulfonylurea_oral_hypoglycemic_agents </e22> , blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary.
advise	Careful monitoring of prothrombin time in patients receiving <e11> DIFLUCAN </e11> and <e22> coumarin-type_anticoagulants </e22> is recommended.
advise	Careful monitoring of phenytoin concentrations in patients receiving <e11> DIFLUCAN </e11> and <e20> phenytoin </e20> is recommended.
advise	Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving <e11> DIFLUCAN </e11> and <e20> cyclosporine </e20> .
advise	Depending on clinical circumstances, consideration should be given to increasing the dose of <e11> DIFLUCAN </e11> when it is administered with <e20> rifampin </e20> .
advise	Careful monitoring of serum theophylline concentrations in patients receiving <e11> DIFLUCAN </e11> and <e20> theophylline </e20> is recommended.
advise	The combined use of <e10> fluconazole </e10> at doses of # mg or greater with <e20> terfenadine </e20> is contraindicated.
advise	The coadministration of <e10> fluconazole </e10> at doses lower than # mg/day with <e20> terfenadine </e20> should be carefully monitored.
advise	The combined use of <e10> fluconazole </e10> with <e20> cisapride </e20> is contraindicated.
advise	Patients receiving <e10> rifabutin </e10> and <e20> fluconazole </e20> concomitantly should be carefully monitored.
advise	Patients receiving <e10> tacrolimus </e10> and <e20> fluconazole </e20> concomitantly should be carefully monitored.
advise	If <e12> short-acting_benzodiazepines </e12> , which are metabolized by the cytochrome P450 system, are concomitantly administered with <e20> fluconazole </e20> , consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored.
advise	You cannot take <e10> mazindol </e10> if you have taken a <e22> monoamine_oxidase_inhibitor </e22> ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil ) in the last # days.
advise	You cannot take <e10> mazindol </e10> if you have taken a monoamine_oxidase_inhibitor ( <e22> MAOI </e22> ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil ) in the last # days.
advise	You cannot take <e10> mazindol </e10> if you have taken a monoamine_oxidase_inhibitor ( MAOI ) such as <e20> isocarboxazid </e20> ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil ) in the last # days.
advise	You cannot take <e10> mazindol </e10> if you have taken a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( <e21> Marplan </e21> ), tranylcypromine ( Parnate ), or phenelzine ( Nardil ) in the last # days.
advise	You cannot take <e10> mazindol </e10> if you have taken a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), <e20> tranylcypromine </e20> ( Parnate ), or phenelzine ( Nardil ) in the last # days.
advise	You cannot take <e10> mazindol </e10> if you have taken a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( <e21> Parnate </e21> ), or phenelzine ( Nardil ) in the last # days.
advise	You cannot take <e10> mazindol </e10> if you have taken a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or <e20> phenelzine </e20> ( Nardil ) in the last # days.
advise	You cannot take <e10> mazindol </e10> if you have taken a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( <e21> Nardil </e21> ) in the last # days.
advise	Changes in <e10> insulin </e10> and other diabetes drug therapies may be necessary during treatment with <e20> mazindol </e20> .
advise	Patients receiving <e12> antibiotics </e12> and sulfonamides generally should not be treated with <e22> ganglion_blockers </e22> .
advise	Patients receiving antibiotics and <e12> sulfonamides </e12> generally should not be treated with <e22> ganglion_blockers </e22> .
advise	Administration of a higher dose of <e10> indinavir </e10> should be considered when coadministering with <e20> megestrol_acetate </e20> .
advise	This interaction should be given consideration in patients taking <e12> NSAIDs </e12> concomitantly with <e22> ACE_inhibitors </e22> .
advise	however, as with other <e12> NSAIDs </e12> , concomitant administration of meloxicam and <e21> aspirin </e21> is not generally recommended because of the potential for increased adverse effects.
advise	however, as with other NSAIDs , concomitant administration of <e10> meloxicam </e10> and <e21> aspirin </e21> is not generally recommended because of the potential for increased adverse effects.
advise	Nevertheless, during concomitant therapy with <e10> furosemide </e10> and <e21> MOBIC </e21> , patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy.
advise	Patients on <e10> lithium </e10> treatment should be closely monitored when <e21> MOBIC </e21> is introduced or withdrawn.
advise	Warfarin : Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing <e11> MOBIC </e11> therapy in patients receiving <e20> warfarin </e20> or similar agents, since these patients are at an increased risk of bleeding.
advise	Caution should be used when administering <e11> MOBIC </e11> with <e20> warfarin </e20> since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.
advise	Interaction with Other Central_Nervous_System_Depressants : <e10> MEPERIDINE </e10> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e22> NARCOTIC_ANALGESICS </e22> , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
advise	Interaction with Other Central_Nervous_System_Depressants : <e10> MEPERIDINE </e10> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL <e22> ANESTHETICS </e22> , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
advise	Interaction with Other Central_Nervous_System_Depressants : <e10> MEPERIDINE </e10> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , <e22> PHENOTHIAZINES </e22> , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
advise	Interaction with Other Central_Nervous_System_Depressants : <e10> MEPERIDINE </e10> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER <e22> TRANQUILIZERS </e22> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
advise	Interaction with Other Central_Nervous_System_Depressants : <e10> MEPERIDINE </e10> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , <e22> SEDATIVE-HYPNOTICS </e22> (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
advise	Interaction with Other Central_Nervous_System_Depressants : <e10> MEPERIDINE </e10> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING <e22> BARBITURATES </e22> ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
advise	Interaction with Other Central_Nervous_System_Depressants : <e10> MEPERIDINE </e10> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), <e22> TRICYCLIC_ANTIDEPRESSANTS </e22> AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
advise	Interaction with Other Central_Nervous_System_Depressants : <e10> MEPERIDINE </e10> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER <e22> CNS_DEPRESSANTS </e22> (INCLUDING ALCOHOL ).
advise	Interaction with Other Central_Nervous_System_Depressants : <e10> MEPERIDINE </e10> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING <e20> ALCOHOL </e20> ).
advise	Therefore, the coadministration of <e10> probenecid </e10> with <e20> meropenem </e20> is not recommended.
advise	Caution is advised for patients receiving high-dose <e11> aspirin </e11> and <e20> methazolamide </e20> concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic_anhydrase_inhibitors .
advise	Exert particular caution in combining <e10> levomepromazine </e10> with other <e22> anticholinergic_drugs </e22> ( tricyclic_antidepressants and antiparkinsonian-agents ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
advise	Exert particular caution in combining <e10> levomepromazine </e10> with other anticholinergic_drugs ( <e22> tricyclic_antidepressants </e22> and antiparkinsonian-agents ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
advise	Exert particular caution in combining <e10> levomepromazine </e10> with other anticholinergic_drugs ( tricyclic_antidepressants and <e22> antiparkinsonian-agents </e22> ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
advise	Since <e11> Celontin </e11> ( methsuximide ) may interact with concurrently administered <e22> antiepileptic_drugs </e22> , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ).
advise	Since Celontin ( <e10> methsuximide </e10> ) may interact with concurrently administered <e22> antiepileptic_drugs </e22> , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ).
advise	Patients may require reduced doses of <e12> anesthetics </e12> when on <e20> methyldopa </e20> .
advise	When <e10> methyldopa </e10> and <e20> lithium </e20> are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity.
advise	Coadministration of <e10> methyldopa </e10> with <e20> ferrous_sulfate </e20> or ferrous_gluconate is not recommended.
advise	Coadministration of <e10> methyldopa </e10> with ferrous_sulfate or <e20> ferrous_gluconate </e20> is not recommended.
advise	Caution should be exercised when <e11> Methergine </e11> ( methylergonovine_maleate ) is used concurrently with other <e22> vasoconstrictors </e22> or ergot_alkaloids .
advise	Caution should be exercised when <e11> Methergine </e11> ( methylergonovine_maleate ) is used concurrently with other vasoconstrictors or <e22> ergot_alkaloids </e22> .
advise	Caution should be exercised when Methergine ( <e10> methylergonovine_maleate </e10> ) is used concurrently with other <e22> vasoconstrictors </e22> or ergot_alkaloids .
advise	Drugs that induce hepatic enzymes such as <e10> phenobarbital </e10> , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in <e20> methylprednisolone </e20> dose to achieve the desired response.
advise	Drugs that induce hepatic enzymes such as phenobarbital , <e10> phenytoin </e10> , and rifampin may increase the clearance of methylprednisolone and may require increased in <e20> methylprednisolone </e20> dose to achieve the desired response.
advise	Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and <e10> rifampin </e10> may increase the clearance of methylprednisolone and may require increased in <e20> methylprednisolone </e20> dose to achieve the desired response.
advise	<e11> Aspirin </e11> should be used cautiously in conjunction with <e22> corticosteroids </e22> in patients suffering from hypoprothrombinemia.
advise	The finding that <e12> metoclopramide </e12> releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving <e22> monoamine_oxi-dase_inhibitors </e22> .
advise	Because the action of <e12> metoclopramide </e12> will influence the delivery of food to the intestines and thus the rate of absorption, <e20> insulin </e20> dosage or timing of dosage may require adjustment.
advise	Other Antihypertensives : When <e11> MYKROX </e11> Tablets are used with other <e22> antihypertensive_drugs </e22> , care must be taken, especially during initial therapy.
advise	Caution should be observed in administering <e11> DEMSER </e11> to patients receiving <e22> phenothiazines </e22> or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.
advise	Caution should be observed in administering <e11> DEMSER </e11> to patients receiving phenothiazines or <e20> haloperidol </e20> because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.
advise	This increase was observed at the first test point which was the second day after starting Mexitil , Theophylline plasma levels returned to pre- Mexitil values within # hours after discontinuing Mexitil , If <e11> Mexitil </e11> and <e20> theophylline </e20> are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil dose is changed.
advise	Patients receiving <e10> sirolimus </e10> or nifedipine in combination with <e21> MYCAMINE </e21> should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
advise	Patients receiving sirolimus or <e10> nifedipine </e10> in combination with <e21> MYCAMINE </e21> should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
advise	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when <e10> midazolam </e10> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of <e22> azole_antimycotics </e22> , protease_inhibitors , calcium_channel_antagonists , and macrolide_antibiotics ).
advise	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when <e10> midazolam </e10> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole_antimycotics , <e22> protease_inhibitors </e22> , calcium_channel_antagonists , and macrolide_antibiotics ).
advise	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when <e10> midazolam </e10> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole_antimycotics , protease_inhibitors , <e22> calcium_channel_antagonists </e22> , and macrolide_antibiotics ).
advise	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when <e10> midazolam </e10> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole_antimycotics , protease_inhibitors , calcium_channel_antagonists , and <e22> macrolide_antibiotics </e22> ).
advise	Combination therapy with <e11> Cerezyme </e11> ( imiglucerase ) and <e21> ZAVESCA </e21> is not indicated.
advise	Combination therapy with Cerezyme ( <e10> imiglucerase </e10> ) and <e21> ZAVESCA </e21> is not indicated.
advise	Because <e12> tetracyclines </e12> have been shown to depress plasma prothrombin activity, patients who are on <e22> anticoagulant </e22> therapy may require downward adjustment of their anticoagulant dosage.
advise	Since bacteriostatic drugs may interfere with the bactericidal action of penicillin , it is advisable to avoid giving <e12> tetracycline_class_drugs </e12> in conjunction with <e20> penicillin </e20> .
advise	If at all possible <e10> guanethidine </e10> should be discontinued well before <e20> minoxidil </e20> is begun.
advise	Accordingly, patients should be advised to avoid <e10> alcohol </e10> while taking <e21> REMERON_SolTab </e21> , Diazepam : Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in # healthy subjects.
advise	Accordingly, patients should be advised to avoid <e10> diazepam </e10> and other similar drugs while taking <e21> REMERON_SolTab </e21> .
advise	Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering <e10> Mitotane </e10> to patients on <e22> coumarin-type_anticoagulants </e22> .
advise	Evidence of spontaneous recovery from <e10> succinylcholine </e10> should be observed before the administration of <e21> MIVACRON </e21> .
advise	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as <e10> phenobarbital </e10> or rifampin , are co-administered with <e20> montelukast </e20> .
advise	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or <e10> rifampin </e10> , are co-administered with <e20> montelukast </e20> .
advise	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as <e10> phenobarbital </e10> or rifampin , are co-administered with <e20> montelukast </e20> .
advise	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or <e10> rifampin </e10> , are co-administered with <e20> montelukast </e20> .
advise	Interaction with Mixed_Agonist/Antagonist_Opioid_Analgesics : <e12> Agonist/antagonist_analgesics </e12> (i,e,, pentazocine , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e22> opioid_agonist_analgesic </e22> .
advise	Interaction with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (i,e,, <e10> pentazocine </e10> , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e22> opioid_agonist_analgesic </e22> .
advise	Interaction with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (i,e,, pentazocine , <e10> nalbuphine </e10> , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e22> opioid_agonist_analgesic </e22> .
advise	Interaction with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (i,e,, pentazocine , nalbuphine , <e10> butorphanol </e10> , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e22> opioid_agonist_analgesic </e22> .
advise	Interaction with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (i,e,, pentazocine , nalbuphine , butorphanol , or <e10> buprenorphine </e10> ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e22> opioid_agonist_analgesic </e22> .
advise	It is recommended that <e11> Myfortic </e11> and <e20> antacids </e20> not be administered simultaneously.
advise	Azathioprine / Mycophenolate_Mofetil : Given that azathioprine and mycophenolate_mofetil inhibit purine metabolism, it is recommended that <e11> Myfortic </e11> not be administered concomitantly with <e20> azathioprine </e20> or mycophenolate_mofetil .
advise	Azathioprine / Mycophenolate_Mofetil : Given that azathioprine and mycophenolate_mofetil inhibit purine metabolism, it is recommended that <e11> Myfortic </e11> not be administered concomitantly with azathioprine or <e20> mycophenolate_mofetil </e20> .
advise	Therefore, do not administer <e11> Myfortic </e11> with <e20> cholestyramine </e20> or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated_charcoal , because of the potential to reduce the efficacy of Myfortic .
advise	Therefore, do not administer <e11> Myfortic </e11> with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral <e20> activated_charcoal </e20> , because of the potential to reduce the efficacy of Myfortic .
advise	Therefore, it is recommended that oral <e12> contraceptives </e12> are co- administered with <e21> Myfortic </e21> with caution and additional birth control methods be considered.
advise	Live_Vaccines : During treatment with <e11> Myfortic </e11> , the use of <e22> live_attenuated_vaccines </e22> should be avoided and patients should be advised that vaccinations may be less effective.
advise	Other <e12> beta_adrenergic_aerosol_bronchodilators </e12> should not be used concomitantly with <e21> Alupent </e21> ( metaproterenol_sulfate USP) because they may have additive effects.
advise	Other <e12> beta_adrenergic_aerosol_bronchodilators </e12> should not be used concomitantly with Alupent ( <e20> metaproterenol_sulfate </e20> USP) because they may have additive effects.
advise	<e12> Beta_adrenergic_agonists </e12> should be administered with caution to patients being treated with <e22> monoamine_oxidase_inhibitors </e22> or tricyclic_antidepressants , since the action of beta_adrenergic_agonists on the vascular system may be potentiated.
advise	<e12> Beta_adrenergic_agonists </e12> should be administered with caution to patients being treated with monoamine_oxidase_inhibitors or <e22> tricyclic_antidepressants </e22> , since the action of beta_adrenergic_agonists on the vascular system may be potentiated.
advise	Therefore, as vitamin_K absorption may be decreased with XENICAL , patients on chronic stable doses of <e10> warfarin </e10> who are prescribed <e21> XENICAL </e21> should be monitored closely for changes in coagulation parameters.
advise	When <e10> oxandrolone </e10> therapy is initiated in a patient already receiving treatment with <e20> warfarin </e20> , the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved.
advise	Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the <e10> warfarin </e10> dosage if indicated are recommended when the <e20> oxandrolone </e20> dose is changed or discontinued.
advise	Given the primary CNS effects of <e10> paliperidone </e10> , INVEGA should be used with caution in combination with other <e22> centrally_acting_drugs </e22> and alcohol .
advise	Given the primary CNS effects of <e10> paliperidone </e10> , INVEGA should be used with caution in combination with other centrally_acting_drugs and <e20> alcohol </e20> .
advise	Given the primary CNS effects of paliperidone , <e11> INVEGA </e11> should be used with caution in combination with other <e22> centrally_acting_drugs </e22> and alcohol .
advise	Given the primary CNS effects of paliperidone , <e11> INVEGA </e11> should be used with caution in combination with other centrally_acting_drugs and <e20> alcohol </e20> .
advise	Patients treated with <e12> proton_pump_inhibitors </e12> and <e20> warfarin </e20> concomitantly should be monitored for increases in INR and prothrombin time.
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with <e20> ketoconazole </e20> and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including <e20> atazanavir </e20> , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including atazanavir , <e20> clarithromycin </e20> , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , <e20> indinavir </e20> , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , <e20> itraconazole </e20> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , <e20> nefazodone </e20> , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , <e20> nelfinavir </e20> , ritonavir , saquinavir , telithromycin or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , <e20> ritonavir </e20> , saquinavir , telithromycin or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , <e20> saquinavir </e20> , telithromycin or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , <e20> telithromycin </e20> or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or <e20> voriconazole </e20> .
advise	Dose adjustment of <e11> Zemplar </e11> Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as <e20> ketoconazole </e20> .
advise	patients receiving <e10> lithium </e10> and <e21> Neulasta </e21> should have more frequent monitoring of neutrophil counts.
advise	Acromegalic patients with diabetes mellitus being treated with <e10> insulin </e10> and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with <e21> SOMAVERT </e21> .
advise	Acromegalic patients with diabetes mellitus being treated with insulin and/or oral <e12> hypoglycemic </e12> agents may require dose reductions of these therapeutic agents after the initiation of therapy with <e21> SOMAVERT </e21> .
advise	Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance # mL/min), caution should be used when administering <e10> ibuprofen </e10> concurrently with <e21> ALIMTA </e21> to patients with mild to moderate renal insufficiency (creatinine clearance from # to # mL/min).
advise	Patients with mild to moderate renal insufficiency should avoid taking <e12> NSAIDs </e12> with short elimination half-lives for a period of # days before, the day of, and # days following administration of <e21> ALIMTA </e21> .
advise	In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these <e12> NSAIDs </e12> should interrupt dosing for at least # days before, the day of, and # days following <e21> ALIMTA </e21> administration.
advise	Usage with Alcohol : Due to the potential for increased CNS depressants effects, <e10> alcohol </e10> should be used with caution in patients who are currently receiving <e20> pentazocine </e20> .
advise	<e12> Dopamine_antagonists </e12> , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with <e21> Permax </e21> (a dopamine_agonist );
advise	Dopamine_antagonists , such as the <e12> neuroleptics </e12> ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with <e21> Permax </e21> (a dopamine_agonist );
advise	Dopamine_antagonists , such as the neuroleptics ( <e12> phenothiazines </e12> , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with <e21> Permax </e21> (a dopamine_agonist );
advise	Dopamine_antagonists , such as the neuroleptics ( phenothiazines , <e12> butyrophenones </e12> , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with <e21> Permax </e21> (a dopamine_agonist );
advise	Dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , <e12> thioxanthines </e12> ) or metoclopramide , ordinarily should not be administered concurrently with <e21> Permax </e21> (a dopamine_agonist );
advise	Dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or <e12> metoclopramide </e12> , ordinarily should not be administered concurrently with <e21> Permax </e21> (a dopamine_agonist );
advise	If <e12> diuretics </e12> cannot be interrupted, close medical supervision should be provided with the first dose of <e21> ACEON </e21> Tablets, for at least two hours and until blood pressure has stabilized for another hour.
advise	<e10> Pilocarpine </e10> should be administered with caution to patients taking <e22> beta_adrenergic_antagonists </e22> because of the possibility of conduction disturbances.
advise	Other <e12> short-acting_beta_adrenergic_aerosol_bronchodilators </e12> should not be used concomitantly with <e21> MAXAIR_AUTOHALER </e21> because they may have additive effects.
advise	Although this has not occurred in in vitro studies with coumarin-type_anticoagulants , interactions with coumarin-type_anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering <e11> FELDENE </e11> to patients on <e22> coumarin-type_anticoagulants </e22> and other highly protein-bound drugs.
advise	It is recommended that plasma <e10> lithium </e10> levels be monitored when initiating, adjusting and discontinuing <e21> FELDENE </e21> .
advise	Due to its effects on gastric emptying, <e11> SYMLIN </e11> therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e,g,, <e22> anticholinergic_agents </e22> such as atropine ) and agents that slow the intestinal absorption of nutrients (e,g,, alpha_glucosidase_inhibitors ).
advise	Due to its effects on gastric emptying, <e11> SYMLIN </e11> therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e,g,, anticholinergic_agents such as <e20> atropine </e20> ) and agents that slow the intestinal absorption of nutrients (e,g,, alpha_glucosidase_inhibitors ).
advise	Due to its effects on gastric emptying, <e11> SYMLIN </e11> therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e,g,, anticholinergic_agents such as atropine ) and agents that slow the intestinal absorption of nutrients (e,g,, <e22> alpha_glucosidase_inhibitors </e22> ).
advise	When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as <e12> analgesics </e12> ), the agent should be administered at least # hour prior to or # hours after <e21> SYMLIN </e21> injection.
advise	<e11> Aspirin </e11> should be used cautiously in conjunction with <e22> corticosteroids </e22> in patients suffering from hypoprothrombinemia.
advise	Because <e11> Matulane </e11> exhibits some monoamine oxidase inhibitory activity, <e22> sympathomimetic_drugs </e22> , tricyclic_antidepressant drugs (e,g,, amitriptyline_HCl , imipramine_HCl ) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
advise	Because <e11> Matulane </e11> exhibits some monoamine oxidase inhibitory activity, sympathomimetic_drugs , <e22> tricyclic_antidepressant </e22> drugs (e,g,, amitriptyline_HCl , imipramine_HCl ) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
advise	Because <e11> Matulane </e11> exhibits some monoamine oxidase inhibitory activity, sympathomimetic_drugs , tricyclic_antidepressant drugs (e,g,, <e20> amitriptyline_HCl </e20> , imipramine_HCl ) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
advise	Because <e11> Matulane </e11> exhibits some monoamine oxidase inhibitory activity, sympathomimetic_drugs , tricyclic_antidepressant drugs (e,g,, amitriptyline_HCl , <e20> imipramine_HCl </e20> ) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
advise	Because <e11> Matulane </e11> exhibits some monoamine oxidase inhibitory activity, sympathomimetic_drugs , tricyclic_antidepressant drugs (e,g,, amitriptyline_HCl , imipramine_HCl ) and other drugs and foods with known high <e23> tyramine </e23> content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
advise	During maintenance of anesthesia or sedation, the rate of <e11> DIPRIVAN </e11> Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental <e22> analgesic_agents </e22> (eg, nitrous_oxide or opioids ).
advise	During maintenance of anesthesia or sedation, the rate of <e11> DIPRIVAN </e11> Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic_agents (eg, <e20> nitrous_oxide </e20> or opioids ).
advise	During maintenance of anesthesia or sedation, the rate of <e11> DIPRIVAN </e11> Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic_agents (eg, nitrous_oxide or <e22> opioids </e22> ).
advise	Cholestyramine : <e10> Cholestyramine </e10> causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with <e21> EVISTA </e21> .
advise	If <e11> EVISTA </e11> is given concurrently with <e20> warfarin </e20> , prothrombin time should be monitored.
advise	Caution should be used when <e11> EVISTA </e11> is coadministered with other highly protein-bound drugs, such as <e20> clofibrate </e20> , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
advise	Caution should be used when <e11> EVISTA </e11> is coadministered with other highly protein-bound drugs, such as clofibrate , <e20> indomethacin </e20> , naproxen , ibuprofen , diazepam , and diazoxide .
advise	Caution should be used when <e11> EVISTA </e11> is coadministered with other highly protein-bound drugs, such as clofibrate , indomethacin , <e20> naproxen </e20> , ibuprofen , diazepam , and diazoxide .
advise	Caution should be used when <e11> EVISTA </e11> is coadministered with other highly protein-bound drugs, such as clofibrate , indomethacin , naproxen , <e20> ibuprofen </e20> , diazepam , and diazoxide .
advise	Caution should be used when <e11> EVISTA </e11> is coadministered with other highly protein-bound drugs, such as clofibrate , indomethacin , naproxen , ibuprofen , <e20> diazepam </e20> , and diazoxide .
advise	Caution should be used when <e11> EVISTA </e11> is coadministered with other highly protein-bound drugs, such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and <e20> diazoxide </e20> .
advise	If <e11> ZEMURON </e11> is administered following administration of <e20> succinylcholine </e20> , it should not be given until recovery from succinylcholine has been observed.
advise	<e10> Ropivacaine </e10> should be used with caution in patients receiving other local <e22> anesthetics </e22> or agents structurally related to amide-type_local_anesthetics , since the toxic effects of these drugs are additive.
advise	Although such a reaction has not been demonstrated with roxithromycin , concomitant administration of <e10> roxithromycin </e10> with <e20> terfenadine </e20> or astemizole is not recommended.
advise	Although such a reaction has not been demonstrated with roxithromycin , concomitant administration of <e10> roxithromycin </e10> with terfenadine or <e20> astemizole </e20> is not recommended.
advise	<e10> Scopolamine </e10> should be used with care in patients taking other drugs that are capable of causing CNS effects such as <e22> sedatives </e22> , tranquilizers , or alcohol .
advise	<e10> Scopolamine </e10> should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives , <e22> tranquilizers </e22> , or alcohol .
advise	<e10> Scopolamine </e10> should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives , tranquilizers , or <e20> alcohol </e20> .
advise	Do not exceed a # mg daily dose of <e11> VESIcare </e11> when administered with therapeutic doses of <e20> ketoconazole </e20> or other potent CYP3A4 inhibitors.
advise	Caution is recommended when administering <e11> NEXAVAR </e11> with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e,g, <e20> irinotecan </e20> ).
advise	Caution is recommended when administering <e10> doxorubicin </e10> with <e21> NEXAVAR </e21> .
advise	Therefore, use of <e10> zidovudine </e10> in combination with <e21> ZERIT </e21> should be avoided.
advise	a reduction of the <e10> doxorubicin </e10> dosage should be considered in patients receiving <e21> ZANOSAR </e21> concurrently.
advise	Concomitant administration of <e11> CHEMET </e11> with other chelation therapy, such as <e20> CaNa_2_EDTA </e20> is not recommended.
advise	Because there is a theoretical basis that these effects may be additive, use of <e10> ergotamine </e10> -containing or ergot-type_medications (like dihydroergotamine or methysergide ) and <e20> sumatriptan </e20> within # hours of each other should be avoided.
advise	Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or <e12> ergot-type_medications </e12> (like dihydroergotamine or methysergide ) and <e20> sumatriptan </e20> within # hours of each other should be avoided.
advise	Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or ergot-type_medications (like <e10> dihydroergotamine </e10> or methysergide ) and <e20> sumatriptan </e20> within # hours of each other should be avoided.
advise	Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or ergot-type_medications (like dihydroergotamine or <e10> methysergide </e10> ) and <e20> sumatriptan </e20> within # hours of each other should be avoided.
advise	Therefore, the use of <e10> sumatriptan_succinate </e10> tablets in patients receiving <e22> MAO-A_inhibitors </e22> is contraindicated , Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan .
advise	If concomitant treatment with <e10> sumatriptan </e10> and an <e22> SSRI </e22> is clinically warranted, appropriate observation of the patient is advised.
advise	However, interactions may be expected and <e11> FLOMAX </e11> capsules should NOT be used in combination with other <e22> alpha-adrenergic_blocking_agents </e22> .
advise	Therefore, <e11> FLOMAX </e11> capsules should be used with caution in combination with <e20> cimetidine </e20> , particularly at doses higher than # mg.
advise	Therefore, caution should be exercised with concomitant administration of <e10> warfarin </e10> and <e21> FLOMAX </e21> capsules.
advise	Concomitant administration of <e10> ketoconazole </e10> and <e20> terfenadine </e20> is contraindicated.
advise	Concomitant administration of <e10> itraconazole </e10> and <e20> terfenadine </e20> is contraindicated.
advise	Due to the chemical similarity of other <e12> azole-type_antifungal_agents </e12> (including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with <e20> terfenadine </e20> is not recommended pending full examination of potential interactions.
advise	Due to the chemical similarity of other azole-type_antifungal_agents (including <e10> fluconazole </e10> , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with <e20> terfenadine </e20> is not recommended pending full examination of potential interactions.
advise	Due to the chemical similarity of other azole-type_antifungal_agents (including fluconazole , <e10> metronidazole </e10> , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with <e20> terfenadine </e20> is not recommended pending full examination of potential interactions.
advise	Due to the chemical similarity of other azole-type_antifungal_agents (including fluconazole , metronidazole , and <e10> miconazole </e10> ) to ketoconazole , and itraconazole , concomitant use of these products with <e20> terfenadine </e20> is not recommended pending full examination of potential interactions.
advise	Concomitant administration of <e10> terfenadine </e10> with <e20> clarithromycin </e20> , erythromycin , or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide_antibiotics , including azithromycin , is not recommended.
advise	Concomitant administration of <e10> terfenadine </e10> with clarithromycin , <e20> erythromycin </e20> , or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide_antibiotics , including azithromycin , is not recommended.
advise	Concomitant administration of <e10> terfenadine </e10> with clarithromycin , erythromycin , or <e20> troleandomycin </e20> is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide_antibiotics , including azithromycin , is not recommended.
advise	Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of <e10> terfenadine </e10> with other <e22> macrolide_antibiotics </e22> , including azithromycin , is not recommended.
advise	Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of <e10> terfenadine </e10> with other macrolide_antibiotics , including <e20> azithromycin </e20> , is not recommended.
advise	Therefore, when concomitant use of <e10> thiabendazole </e10> and <e22> xanthine_derivatives </e22> is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds.
advise	Caution should be exercised when administering <e11> ZADAXIN </e11> therapy in combination with other <e22> immunomodulating_drugs </e22> .
advise	Prothrombin time or other suitable anticoagulation test should be monitored if <e10> tigecycline </e10> is administered with <e20> warfarin </e20> .
advise	However, the co administration of <e11> SPIRIVA </e11> with other <e22> anticholinergic </e22> containing drugs (e,g,, ipratropium ) has not been studied and is therefore not recommended.
advise	However, the co administration of <e11> SPIRIVA </e11> with other anticholinergic containing drugs (e,g,, <e20> ipratropium </e20> ) has not been studied and is therefore not recommended.
advise	<e11> TOBI </e11> should not be administered concomitantly with <e20> ethacrynic_acid </e20> , furosemide , urea , or mannitol .
advise	<e11> TOBI </e11> should not be administered concomitantly with ethacrynic_acid , <e20> furosemide </e20> , urea , or mannitol .
advise	<e11> TOBI </e11> should not be administered concomitantly with ethacrynic_acid , furosemide , <e20> urea </e20> , or mannitol .
advise	<e11> TOBI </e11> should not be administered concomitantly with ethacrynic_acid , furosemide , urea , or <e20> mannitol </e20> .
advise	Therefore, caution should be exercised when administering <e11> TOLECTIN </e11> to patients on <e22> anticoagulants </e22> .
advise	Caution should be used if <e11> TOLECTIN </e11> is administered concomitantly with <e20> methotrexate </e20> .
advise	For patients receiving <e10> ketoconazole </e10> or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , miconazole ) or macrolide_antibiotics (eg, erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of <e21> DETROL_LA </e21> is # mg daily.
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e12> azole_antifungals </e12> (eg, itraconazole , miconazole ) or macrolide_antibiotics (eg, erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of <e21> DETROL_LA </e21> is # mg daily.
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, <e10> itraconazole </e10> , miconazole ) or macrolide_antibiotics (eg, erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of <e21> DETROL_LA </e21> is # mg daily.
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , <e10> miconazole </e10> ) or macrolide_antibiotics (eg, erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of <e21> DETROL_LA </e21> is # mg daily.
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , miconazole ) or <e12> macrolide_antibiotics </e12> (eg, erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of <e21> DETROL_LA </e21> is # mg daily.
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , miconazole ) or macrolide_antibiotics (eg, <e10> erythromycin </e10> , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of <e21> DETROL_LA </e21> is # mg daily.
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , miconazole ) or macrolide_antibiotics (eg, erythromycin , <e10> clarithromycin </e10> ) or cyclosporine or vinblastine , the recommended dose of <e21> DETROL_LA </e21> is # mg daily.
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , miconazole ) or macrolide_antibiotics (eg, erythromycin , clarithromycin ) or <e10> cyclosporine </e10> or vinblastine , the recommended dose of <e21> DETROL_LA </e21> is # mg daily.
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , miconazole ) or macrolide_antibiotics (eg, erythromycin , clarithromycin ) or cyclosporine or <e10> vinblastine </e10> , the recommended dose of <e21> DETROL_LA </e21> is # mg daily.
advise	Physicians should carefully monitor PT and INR in patients concurrently administered <e11> ZOLINZA </e11> and <e22> coumarin_derivatives </e22> .
